Table 3.
Discussions at patient-provider visits
| All participants | All non-routine recommendations | Disease-specific non-routine recommendations | ||
|---|---|---|---|---|
| Breast Cancer∞ |
|
|
|
|
| |
Risk of breast cancer |
48 (22.8%) |
29 (23.2%) |
18 (32.7%) |
| |
Mammography |
125 (59.2%) |
68 (54.4%) |
33 (60.0%) |
| |
Breast MRI |
10 (4.7%) |
8 (6.4%) |
5 (9.1%) |
| |
Tamoxifen |
6 (2.8%) |
5 (4%) |
4 (7.3%) |
| Ovarian Cancer∞ |
|
19 (9.0%) |
13 (10.4%) |
6 (50%) |
| Colon cancer* |
|
|
|
|
| |
Risk of colon cancer |
113 (30.5%) |
50 (29.2%) |
39 (34.8%) |
| |
Screening for colon cancer |
260 (70.3%) |
118 (69.0%) |
83 (74.1%) |
| Thrombosis* |
|
35 (9.5%) |
18 (10.5%) |
10 (41.7%) |
| Seeing a specialist* |
|
82 (22.2%) |
62 (36.3%) |
n/a |
| Lifestyle choices* | 192 (51.9%) | 83 (48.5%) | n/a |
∞Total N = 211 for all participants; 125 for all non-routine recommendations; 55 for breast cancer-specific non-routine recommendations; 12 for ovarian cancer-specific non-routine recommendations.
*Total N = 370 for all participants; 171 for all non-routine recommendations; 112 for colon cancer-specific non-routine recommendations; 24 for thrombosis-specific non-routine recommendations.